Compare ProShares Ultra QQQ ETF (QLD) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra QQQ ETF vs Recursion Pharmaceuticals Inc — how do they compare? ProShares Ultra QQQ ETF trades at $98.33 (market cap $15.38B), while Recursion Pharmaceuticals Inc trades at $3.93 (market cap $2.14B). The key difference: ProShares Ultra QQQ ETF is far larger — about 7.2× Recursion Pharmaceuticals Inc's market cap, and ProShares Ultra QQQ ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares Ultra QQQ ETF for 37 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| QLD | RXRX | |
|---|---|---|
Market Cap | $15.38B | $2.14B |
Volume | 4,844,085 | 30,789,535 |
Sector | Leveraged / Inverse | Health |
52-Week High | $100.77 | $6.79 |
52-Week Low | $57.16 | $2.84 |
Typical Hold Time | 37 Days | 22 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QLD trades at $100.23, down 0.54% on the day, with technical indicators showing a bullish moving average signal but overbought RSI conditions. The ETF maintains support at $99 and resistance at $101, with institutional buying activity noted in recent filings. Recent news highlights QLD's resilience compared to more leveraged alternatives during market downturns.
The outlook remains cautiously optimistic given strong technical momentum, though overbought conditions suggest potential near-term consolidation. Key risks include Federal Reserve policy impacts and Nasdaq volatility, while institutional accumulation supports medium-term bullish sentiment.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
